Zymeworks Inc
ZYME22.720USD
+0.700+3.18%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
1.72BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Zymeworks Inc Unternehmen
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
Zymeworks Inc Informationen
BörsenkürzelZYME
Name des UnternehmensZymeworks Inc
IPO-datumJun 24, 2019
CEOGalbraith (Kenneth H)
Anzahl der mitarbeiter280
WertpapierartOrdinary Share
GeschäftsjahresendeJun 24
Addresse108 Patriot Drive, Suite A
StadtMIDDLETOWN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl19709
Telefon13022748744
Websitehttps://www.zymeworks.com/
BörsenkürzelZYME
IPO-datumJun 24, 2019
CEOGalbraith (Kenneth H)
Führungskräfte von Zymeworks Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Dr. Paul A. Moore, Ph.D.
Dr. Paul A. Moore, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Acting Chief Investment Officer
Acting Chief Investment Officer
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
Dr. Jeffrey Smith, M.D.
Dr. Jeffrey Smith, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Dr. Paul A. Moore, Ph.D.
Dr. Paul A. Moore, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, Feb 1
Aktualisiert: Sun, Feb 1
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
EcoR1 Capital, LLC
30.69%
Rubric Capital Management LP
6.29%
BVF Partners L.P.
5.26%
Morgan Stanley & Co. LLC
5.23%
Redmile Group, LLC
4.95%
Andere
47.56%
Aktionäre
Aktionäre
Anteil
EcoR1 Capital, LLC
30.69%
Rubric Capital Management LP
6.29%
BVF Partners L.P.
5.26%
Morgan Stanley & Co. LLC
5.23%
Redmile Group, LLC
4.95%
Andere
47.56%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
51.31%
Investment Advisor
20.98%
Hedge Fund
18.80%
Research Firm
6.53%
Private Equity
2.79%
Individual Investor
1.24%
Venture Capital
0.28%
Sovereign Wealth Fund
0.27%
Pension Fund
0.25%
Institutionelle Beteiligung
Aktualisiert: Wed, Jan 21
Aktualisiert: Wed, Jan 21
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q4
333
74.80M
105.96%
--
2025Q4
404
76.14M
101.75%
-5.97M
2025Q3
390
74.41M
99.43%
-2.56M
2025Q2
383
76.90M
102.73%
+2.83M
2025Q1
400
71.70M
97.61%
-1.37M
2024Q4
389
68.69M
99.73%
-8.79M
2024Q3
388
74.13M
105.03%
-25.13M
2024Q2
387
74.77M
106.29%
-27.88M
2024Q1
389
74.54M
106.20%
-28.73M
2023Q4
388
72.09M
103.65%
-29.69M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
EcoR1 Capital, LLC
22.97M
30.69%
--
--
Nov 16, 2025
Rubric Capital Management LP
4.71M
6.29%
--
--
Sep 30, 2025
BVF Partners L.P.
3.94M
5.26%
-370.29K
-8.59%
Sep 30, 2025
Morgan Stanley & Co. LLC
3.92M
5.23%
+295.26K
+8.15%
Sep 30, 2025
Redmile Group, LLC
3.71M
4.95%
-444.88K
-10.72%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.12M
4.17%
+11.88K
+0.38%
Sep 30, 2025
The Vanguard Group, Inc.
2.15M
2.87%
-310.26K
-12.63%
Sep 30, 2025
Perceptive Advisors LLC
2.09M
2.79%
+815.39K
+63.94%
Sep 30, 2025
Vestal Point Capital, LP
1.76M
2.36%
+615.00K
+53.48%
Sep 30, 2025
Blackstone Alternative Asset Management, L.P.
1.62M
2.16%
-40.50K
-2.44%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Tema Oncology ETF
2.25%
Virtus LifeSci Biotech Clinical Trials ETF
0.99%
ProShares Ultra Nasdaq Biotechnology
0.24%
iShares Micro-Cap ETF
0.18%
Federated Hermes MDT Small Cap Core ETF
0.15%
WisdomTree US SmallCap Quality Growth Fund
0.15%
SPDR S&P International Small Cap ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
iShares Biotechnology ETF
0.12%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.12%
Mehr Anzeigen
Tema Oncology ETF
Anteil2.25%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.99%
ProShares Ultra Nasdaq Biotechnology
Anteil0.24%
iShares Micro-Cap ETF
Anteil0.18%
Federated Hermes MDT Small Cap Core ETF
Anteil0.15%
WisdomTree US SmallCap Quality Growth Fund
Anteil0.15%
SPDR S&P International Small Cap ETF
Anteil0.14%
Invesco Nasdaq Biotechnology ETF
Anteil0.14%
iShares Biotechnology ETF
Anteil0.12%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Anteil0.12%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
